SCHRODINGER INC

Company Overview

Schrödinger Inc. is a Healthcare company in the Health Information Services industry that combines computational chemistry software with drug discovery collaborations. Its physics-based platform is used by biopharmaceutical companies, academic institutions, and industrial customers to design molecules, predict properties, and speed lead optimization, while its internal drug discovery efforts support partnered and proprietary programs. In 2025, the company reported $255.9 million in revenue and continued to shift toward hosted software subscriptions and large commercial accounts, with all of the top 20 pharmaceutical companies licensing its software. The business remains research-intensive and unprofitable, but it has a strong cash position and meaningful global customer adoption.

Executive Compensation Practices

Executive compensation at Schrödinger is likely tied to a mix of revenue growth, ACV expansion, collaboration milestones, operating discipline, and pipeline progress, which fits a company that spans both software and biotech-style drug discovery. The 2025 results suggest incentives may emphasize the shift to recurring hosted revenue, growth in average ACV per commercial customer, and successful execution of collaborations such as Novartis and Lilly, rather than near-term profitability alone. Because management is also reducing R&D and restructuring headcount to improve operating leverage, compensation plans may include metrics around cost control, cash runway, and disciplined prioritization of programs like SGR-1505 and SGR-3515. For a company with negative net income, equity-based compensation is especially important to align executives with long-term value creation across both software adoption and drug development optionality.

Insider Trading Considerations

Insider trading patterns at Schrödinger may be influenced by lumpy collaboration revenue, trial-stage clinical developments, and the timing shift between on-premise and hosted software contracts. Because revenue can swing when a partner advances, stops, or reclassifies a program, insiders may be cautious around material nonpublic information tied to partnership updates, milestone recognition, or clinical safety events like the discontinuation of SGR-2921. The company’s strong cash balance and 24-month liquidity outlook reduce immediate financing pressure, but insiders may still react to changes in R&D spending, restructuring actions, and the pace of hosted software adoption, which is central to the business model. As a Healthcare company with drug discovery activities, trading windows may also be constrained by clinical and regulatory developments, making transaction timing especially sensitive around trial data, collaboration announcements, and FDA-related updates.